EBioMedicine (Oct 2016)

Integrative Modeling Reveals Annexin A2-mediated Epigenetic Control of Mesenchymal Glioblastoma

  • Teresia Kling,
  • Roberto Ferrarese,
  • Darren Ó hAilín,
  • Patrik Johansson,
  • Dieter Henrik Heiland,
  • Fangping Dai,
  • Ioannis Vasilikos,
  • Astrid Weyerbrock,
  • Rebecka Jörnsten,
  • Maria Stella Carro,
  • Sven Nelander

DOI
https://doi.org/10.1016/j.ebiom.2016.08.050
Journal volume & issue
Vol. 12, no. C
pp. 72 – 85

Abstract

Read online

Glioblastomas are characterized by transcriptionally distinct subtypes, but despite possible clinical relevance, their regulation remains poorly understood. The commonly used molecular classification systems for GBM all identify a subtype with high expression of mesenchymal marker transcripts, strongly associated with invasive growth. We used a comprehensive data-driven network modeling technique (augmented sparse inverse covariance selection, aSICS) to define separate genomic, epigenetic, and transcriptional regulators of glioblastoma subtypes. Our model identified Annexin A2 (ANXA2) as a novel methylation-controlled positive regulator of the mesenchymal subtype. Subsequent evaluation in two independent cohorts established ANXA2 expression as a prognostic factor that is dependent on ANXA2 promoter methylation. ANXA2 knockdown in primary glioblastoma stem cell-like cultures suppressed known mesenchymal master regulators, and abrogated cell proliferation and invasion. Our results place ANXA2 at the apex of a regulatory cascade that determines glioblastoma mesenchymal transformation and validate aSICS as a general methodology to uncover regulators of cancer subtypes.

Keywords